MX2022008746A - Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos. - Google Patents
Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos.Info
- Publication number
- MX2022008746A MX2022008746A MX2022008746A MX2022008746A MX2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- treating diseases
- peptide compounds
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL272074A IL272074B2 (en) | 2020-01-15 | 2020-01-15 | Peptide compounds and methods of treating diseases using same |
| PCT/IL2021/050044 WO2021144798A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008746A true MX2022008746A (es) | 2022-10-13 |
Family
ID=76863930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008746A MX2022008746A (es) | 2020-01-15 | 2021-01-14 | Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230049549A1 (enExample) |
| EP (1) | EP4090347A1 (enExample) |
| JP (1) | JP7809060B2 (enExample) |
| KR (1) | KR20220145826A (enExample) |
| CN (6) | CN119708144A (enExample) |
| AU (1) | AU2021207415A1 (enExample) |
| BR (1) | BR112022013978A2 (enExample) |
| CA (1) | CA3167139A1 (enExample) |
| CO (1) | CO2022011101A2 (enExample) |
| IL (1) | IL272074B2 (enExample) |
| MX (1) | MX2022008746A (enExample) |
| WO (1) | WO2021144798A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| WO2003037172A2 (en) * | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| US8648045B2 (en) * | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| US20130096070A1 (en) * | 2009-04-07 | 2013-04-18 | University Of Kansas | Peptide targeting of inner ear cells |
| CA2836503C (en) * | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| IL280101B2 (en) * | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
-
2020
- 2020-01-15 IL IL272074A patent/IL272074B2/en unknown
-
2021
- 2021-01-14 US US17/792,787 patent/US20230049549A1/en active Pending
- 2021-01-14 EP EP21704023.7A patent/EP4090347A1/en active Pending
- 2021-01-14 CN CN202411888874.5A patent/CN119708144A/zh active Pending
- 2021-01-14 KR KR1020227028077A patent/KR20220145826A/ko active Pending
- 2021-01-14 JP JP2022542986A patent/JP7809060B2/ja active Active
- 2021-01-14 CN CN202411888865.6A patent/CN119708140A/zh active Pending
- 2021-01-14 CN CN202411888870.7A patent/CN119708142A/zh active Pending
- 2021-01-14 CN CN202411888869.4A patent/CN119708141A/zh active Pending
- 2021-01-14 CA CA3167139A patent/CA3167139A1/en active Pending
- 2021-01-14 CN CN202411888873.0A patent/CN119708143A/zh active Pending
- 2021-01-14 CN CN202180017719.4A patent/CN115942948B/zh active Active
- 2021-01-14 AU AU2021207415A patent/AU2021207415A1/en active Pending
- 2021-01-14 MX MX2022008746A patent/MX2022008746A/es unknown
- 2021-01-14 BR BR112022013978A patent/BR112022013978A2/pt unknown
- 2021-01-14 WO PCT/IL2021/050044 patent/WO2021144798A1/en not_active Ceased
-
2022
- 2022-08-04 CO CONC2022/0011101A patent/CO2022011101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021144798A1 (en) | 2021-07-22 |
| CN119708141A (zh) | 2025-03-28 |
| JP7809060B2 (ja) | 2026-01-30 |
| CN115942948A (zh) | 2023-04-07 |
| CA3167139A1 (en) | 2021-07-22 |
| EP4090347A1 (en) | 2022-11-23 |
| US20230049549A1 (en) | 2023-02-16 |
| CN119708142A (zh) | 2025-03-28 |
| CO2022011101A2 (es) | 2022-11-08 |
| AU2021207415A1 (en) | 2022-09-08 |
| CN119708144A (zh) | 2025-03-28 |
| JP2023510019A (ja) | 2023-03-10 |
| IL272074B2 (en) | 2024-12-01 |
| CN119708143A (zh) | 2025-03-28 |
| IL272074A (en) | 2021-07-29 |
| CN115942948B (zh) | 2025-01-14 |
| BR112022013978A2 (pt) | 2022-10-11 |
| CN119708140A (zh) | 2025-03-28 |
| KR20220145826A (ko) | 2022-10-31 |
| IL272074B1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
| CL2018003322A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) | |
| CO2021016768A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
| CO2021016765A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
| CL2021000387A1 (es) | Compuestos de anillo fusionado | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| CO2022000260A2 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| MX2022003063A (es) | Composiciones terapeuticas, combinaciones y metodos de uso. | |
| MX2020012273A (es) | Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos. | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| AR069409A1 (es) | Variantes de peptidos natriureticos de tipo c | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| PE20260442A1 (es) | Composiciones y metodos para tratar la enfermedad celiaca | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| CL2025002554A1 (es) | Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer. | |
| MX2022003671A (es) | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. | |
| CO2018011819A2 (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| MX2022008746A (es) | Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos. | |
| CO2019003865A2 (es) | Proteína terapéutica | |
| CL2025002105A1 (es) | Proteínas de fusión fc de il-12 |